

- + easily mixes into most foods & beverages without altering taste or texture
- + adds nutrients without increasing dietary volume
- + promote increases in fat-free mass




# PROMOTE WELLBEING

WITH

**enū** PRO 3+  
NUTRITION

- + Complete Macronutrient Profile
- + Fortified with Leucine and 28 vitamins and minerals
- + Add to favorite foods or drinks
- + Does not alter taste or texture




Introduction . . . . .	4
Nutrition Support in Cancer. . . . .	6
Nutritional Intervention for Cancer Patients . . . . .	10
Benefits of Whey Protein . . . . .	10
The Role of Leucine in Cachexia . . . . .	12
The role of Zinc in Oncology Nutritional Support. . . . .	13
Recommended Serving Size and Nutrition Facts . . . . .	14
Flexible and Convenient for Greater Adherence . . . . .	15
Bibliographic References . . . . .	16


# INTRODUCTION

ACS estimated  
**1.7**  
 million  
 new cases of  
**CANCER**  
 in the U.S.  
 during **2019**.

According to the World Health Organization, human malignant neoplasia has become one of the main causes of morbi-mortality, attaining approximately 14 million people per year in the world, lung, prostate, bowel and stomach cancer being the most common among men and breast, bowel, lung and neck of the uterus the most common types in women. In the U.S. the American Cancer Society (ACS) estimates 1.7 million new cases of cancer in 2019 (TABLE 1) <sup>68</sup>.



**TABLE 1:** Estimate for incidence of cancer in the United States, 2019.



Cancer incidence is rising. **About 606,000 Americans are expected to die from cancer in 2019** <sup>68</sup>.

Due to these figures, cancer has been considered by many to be a public health problem, especially as it can be prevented, or even avoided, with educational measures of the population to control environmental carcinogenic agents and healthy life habits, as suitable nutrition and physical exercise, etc.<sup>2,3</sup>. The Union for International Cancer Control (UICC) stated in its latest report that more than a third of the most common types of cancer can be prevented through diet, maintenance of

healthy weight and regular practice of physical activity<sup>4</sup>.

The success of the therapy employed is directly related to the nutritional state of the oncological patient. The aggressiveness and localization of the tumor, the organs involved, the clinical, immunological and nutritional conditions imposed by the disease and made worse by late diagnosis and the therapy are factors which can jeopardize the nutritional state, with serious prognostic implications, and interfere directly in the treatment<sup>2,3</sup>

**MORE THAN**



**of the types of cancer** can be **prevented** through **diet, maintenance of healthy weight** and **regular practice of physical activity.**

# NUTRITION SUPPORT IN CANCER

In the Brazilian Oncological Nutrition Inquiry, of INCA, of 2013, 4,822 oncological patients admitted in 45 Brazilian institutions were evaluated, by means of the Patient Generated - Subjective Global Assessment (PG-SGA). Malnutrition or nutritional risk were present in 2,176 (45.1%) patients studied<sup>5</sup>. PG-SGA is one of the tools validated for nutritional evaluating and sorting for oncological patients.

In this context, the new guideline of ESPEN (2016) strongly recommend to detect nutritional disturbances at an early stage with regularly evaluate nutritional intake, weight change and BMI<sup>6</sup>.

In a recent analysis with more than 8160 European and Canadian oncological patients the researchers developed a classification system far loss of weight in cancer which incorporates dimensions of percentage of weight loss (**%WL**) and of **Body Mass Index (BMI)** and **links them to survival (Figure 2). The data represents the spectrum of these features in patients with cancer and showed that %WL and BMI foresee the survival regardless of the conventional prognostic factors, including the cancer's location, stage and performance status<sup>7</sup>.**

The catabolic alterations in the patient with cancer begin

by inadequate nutritional consumption which is characterized as being present, if the patient cannot eat for more than a week, or if the consumption is less than 60% of the energy requirement for more than one or two weeks<sup>6</sup>.


The oncological patient can also have an increase in requirements or loss, decrease in the absorption and/or use of nutrients and Immunoinflammatory response which increases metabolism, generating a hypercatabolic inflammatory state<sup>8</sup>.

The presence of the syndrome anorexia-cachexia is often a complication in the advanced states of neoplastic disease.

% weight loss	BMI (kg/m <sup>2</sup> )	≥28	25 to 27.9	22 to 24.9	20 to 21.9	<20
≤2.4		0	0	1	1	3
2.5 to 5.9		1	2	2	2	3
6 to 10.9		2	3	3	3	4
11 to 14.9		3	3	3	4	4
≥15		3	4	4	4	4

**TABLE 2:** The average survival times by grade were as follows: Grade 0: 20.9 months; Grade 1: 14.6 months; Grade 2: 10.8 months; Grade 3: 7.6 months and Grade 4: 4.3 months. P<.001. Adapted from 7.

**Figure 1:** Development of cachexia in oncological patient (Source: 8 and 9).



**Cachexia is defined as a multifactorial syndrome characterized by constant and progressive loss of skeletal lean body mass** (accompanied or not by loss of fat mass), which cannot be totally reverted by means of conventional nutritional support, and has as a consequence the loss of functional capacity of the individual. The pathophysiology involved in the syndrome is described as a negative proteic and energy balance, resulting from a combination of variables as reduced food ingestion and a series of metabolic alterations<sup>10</sup>. The latter are caused by complex interactions between inflammation (pro-inflammatory cytokines),

neurohormonal alterations and factors potentially proteolytic and lipolytic produced by the tumor and its host<sup>11</sup>. Cachexia of cancer is a continuous process and has three stages of

clinical relevance: precachexia, cachexia, and refractory cachexia. Not all patients undergo all these stages, which can be described in the following manner (TABLE 3)<sup>12</sup>.

**TABLE 3:** Classification of Neoplastic Cachexia

TYPE	DESCRIPTION
PRECACHEXIA	Anorexia, intolerance to glucose
CACHEXIA	Unintentional recent weight loss exceeding 5% of customary in the last 6 months, or body mass index (BMI) less than 20 kg/m <sup>2</sup> associated with unintentional recent weight loss exceeding 2% or sarcopenia associated with recent weight loss exceeding 2%
REFRACTORY CACHEXIA	Result of terminal disease or when, in the presence of rapidly progressive disease, it does not respond to antineoplastic therapy; index ECOG* 3 or 4 associated with life expectancy of less than 3 months

\* ECOG - Eastern Cooperative Oncology Group

# NUTRITION SUPPORT IN CANCER

Weight loss is reported as being the predominant factor regardless of poor prognosis<sup>13,14</sup> and up to 20% of all deaths related to cancer arise from cachexia<sup>15,16,17</sup>. At the moment of the diagnosis, approximately 80% of the patients with tumors in upper GIT have substantial weight loss. The frequency and severity of the malnutrition are greater in those with malignant as gastrointestinal and lung diseases, there being less risk of weight loss in those with breast cancer, leukemia, sarcoma and lymphoma<sup>18</sup>. **Neoplastic patients, besides the factors related to the disease, those related to the treatment also contribute to the worsening of the nutritional state by interference in food ingestion.**

Approximately 30% of chemotherapeutic agents induce nausea and vomiting, cisplatin being considered to be



UP TO  
**20%** of deaths  
related to **cancer**  
arise from **CACHEXIA**

the agent of greatest emetogenic potential. Diarrhea and mucositis occur due to the action of the chemotherapeutic agents in the cellular cycle of cells of quick division, leading to functional mucous alterations. The chemotherapeutic agents most associated with diarrhea are: cytarabine, fluorouracil, topotecan, actinomycin D, oxaliplatin and nitrosoureas. Mucositis is associated with odynophagia, bleeding and local infection, having as main agents o methotrexate, fluo- rouracil, bleomycin, doxorubicin, cisplatin, vincristine and vimblastine. Xerostomia is caused by the competition of the chemotherapeutic agents with receptors of acetylcholine neurotransmitters, which prevent the transmission of parasympathetic impulses of the salivary cells and occurs more frequency in women and the elderly<sup>19</sup>.

Radiotherapy, when employed, is also associated with symptoms and alterations which impair appropriate nutrition. The alterations occurring can be countless, and are related to the place irradiated, as per TABLE 4 at the side:




Adverse effects of **RADIO-THERAPY.**

**TABLE 4:** Classification of Neoplastic Cachexia

PLACE	ADVERSE EFFECTS
CENTRAL NERVOUS SYSTEM	Anorexia, nausea, vomiting
HEAD AND NECK	Mucositis, dysphagia, xerostomia, odynophagia, dysgeusia, dysosmia, anorexia.
THORAX	Dysphagia, odynophagia, esophagitis, nausea, vomiting.
ABDOMEN AND PELVIS	Nausea, vomiting, diarrhea, fistulas, actinic enteritis.

*Adapted from Augusto ALP, In: Cotrim, TH20.*

The loss of muscle mass (also known as sarcopenia), which can be accompanied by loss of function and strength, is directly related to the increase of toxicity to chemotherapy, including in the obese. Sarcopenic obesity is present in 15 to 36% of the obese with neoplasia. The outcomes associated with such condition are,

besides greater toxicity to chemotherapy, an increase in the occurrence of surgical complications, physical incapacity and reduced global survival<sup>21,22</sup>. Besides neoplasia, muscular catabolism is a serious complication of a variety of other diseases and conditions, such as cardiac insufficiency, sepsis,

besides aging, situations of disuse and muscular dystrophy<sup>23</sup>. These other conditions, are often superimposed in oncological patients, worsening their nutritional state. **Regardless of the cause, the proteic degradation is associated with impairment of life quality and poor prognosis of associated pathologies.**

# NUTRITIONAL INTERVENTION

## FOR CANCER PATIENTS


Considering the impact of the nutritional state on the treatment and evolution of neoplastic diseases, early and suitable nutritional intervention becomes essential, as indicated by the guideline of ESPEN for the oncological patient of 2016<sup>6</sup>. In accordance with that stipulated, the nutritional intervention must include nutritional advice, the treatment of the symptoms of the gastrointestinal tract which impair food ingestion and the indication of nutritional supplement, aiming at increasing oral supply.

Feeding by oral means is the most physiological manner of increasing the daily nutritional provision. Nevertheless, it is not always possible to attain the requirement only by means of food in individuals affected by advanced age, fragility, chronic diseases, and the effects of anti-neoplastic therapy. Baldwin et al<sup>24</sup> Ravasco et al<sup>25</sup> found that individualized nutritional

advice associated with the use of oral nutritional supplements (SNO), separately or together, are two of the strategies aiming at increasing the daily proteic and energy supply. In the meta-analysis of Baldwin, the studies were able to indicate that the nutritional intervention was associated with a large energy increase of 430 kcal/day, a weight gain of 1.9kg, **besides the positive effect on the patient's life quality.**

## BENEFITS OF WHEY PROTEIN

The isolate whey protein leads to large benefits for the patient in nutritional therapy, as the capacity of promoting better gastric emptying. The latter is quicker, nevertheless, the remaining in the bowel is increased, which ensures a better digestion and absorption, attaining higher



provides daily

**630** kcal and **39.4** grams of **PROTEIN.**

\*as part of an 1500-2100 kcal daily diet for 70 kg adult  
\*Nutrition values using 18 scoops/day

levels of circulating amino acids, i.e., greater retention of nitrogen, quicker than other sources of protein<sup>26, 27, 28</sup>.

The anticarcinogenic, immunostimulatory and anti-inflammatory effects of whey protein and its peptides have been extensively studied for prevention and treatment

of cancer in models in vitro, animals and in humans <sup>26, 27, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39</sup>.

A study with intestinal Caco-2 cells showed that whey protein had an anti-inflammatory effect by reducing the production of IL-826. In their recent work, Silva et al<sup>27</sup> used models of human umbilical vein endothelial cells (HUVEC) with response TNF-a induced or not, showing that whey protein have several effects in inflammatory gene expression. The beneficial effect of whey protein can be mediated by the presence of branched-chain amino acids (BCAA), by reducing the inflammatory response in model HUVEC with response TNF-a induced.

A recent review of 52 clinical studies in humans supports the idea that dairy products have better anti-inflammatory effects in individuals with metabolic disturbances than in healthy individuals. In accordance

with the categories of dairy products the data stratification showed that as opposed to the high fat content products, **none of the results from studies with low fat content products indicated a pro-inflammatory activity.**

The pro-inflammatory activity identified in the group with whole fat dairy products was attributed mainly to the presence of saturated fat. In the review 50 inflammatory markers possibly involved in the effects investigated were identified<sup>40</sup>. The reduction of the inflammation of low degree in healthy adults was also correlated with the ingestion of dairy products in the stud ATTICA (3,042 individuals)<sup>41</sup>.

Another recent review showed a series of benefits of whey protein besides anti-inflammatory, immunostimulatory and antitumor properties, as antioxidant, hypotensive, intestinal homeostatic, anti-obesity, antidiabetic, muscular

biosynthesis, osteoprotective and dermo-protective<sup>42</sup>.

The supplementation with whey protein was studied in the capacity of pre-operative functional progress and recovery in cancer patients undergoing colorectal resection for cancer showing significant clinical improvements in the patients<sup>43</sup>.



has  
**60% Isolated  
Whey Protein,**  
**23% Concentrate  
Whey Protein**  
**17% L-leucine**  
in its proteic composition,  
with only  
**3% of Saturated Fat** in  
the lipid composition.

## THE ROLE OF **LEUCINE** IN CACHEXIA

The reduced active synthesis of proteins receives the term anabolic resistance and can be seen in conditions as immobilization, aging, cachexia of cancer and sepsis<sup>4</sup>.

Cachectic patients in parenteral nutrition (PN) supplemented with branched-chain amino acids (BCAA) showed an increase in the flow of leucine and proteic synthesis, while protein breakdown remained stable<sup>45</sup>. Another study with patients in PN showed improvement in the proteic development and synthesis of albumin in patients supplemented with BCAA<sup>46</sup>.

In oncological patients losing weight, the administration of amino acids (including doses of branched-chain amino acids) seems to have been beneficial related to loss of muscle mass and proteic synthesis, as per review published by Bozzetti<sup>47</sup>.

Leucine is studied as the BCAA with the greatest

role in proteic synthesis<sup>48</sup>.

In a recent study, supplementation with leucine preserved the anabolic cellular signaling during periods of physical inactivity and had a partial protective effect in body composition and results of the muscle function<sup>49</sup>.

In the elderly it is well debated that supplementation with leucine improves the response of muscle proteic synthesis<sup>50, 51, 52, 53, 54</sup>. In this context, Bauer<sup>55</sup> used supplementation of vitamin D, with 40 grams of whey protein + 6 grams of leucine.

In mice with tumor, supplementation of leucine provides significant protection of skeletal muscle mass<sup>56</sup>.

Recent work in humans suggests that patients with cachexia induced by anabolic pulmo-resistance and impaired muscular anabolism benefit from the simultaneous supplementation of insulin and amino acids<sup>57</sup>. Some mechanisms possibly

involved in the regulatory effects of leucine on proteic synthesis are: the increased availability of substratum and secretion of anabolic hormones as insulin; and the modulation of anabolic routes in skeletal muscle<sup>44</sup>.




provides  
**~1.2**  
grams of  
**LEUCINE**

**2** scoops  


# THE ROLE OF ZINC IN ONCOLOGY NUTRITIONAL SUPPORT

Present in enzymes and proteins which participate in the metabolism of proteins, carbohydrates, lipids and nucleic acids, **zinc can have a catalytic or structural function, its deficiency being able to cause reduced carbonic anhydrase, disturbances of the palate (dysgeusia and hypogeusia) and xerostomia**<sup>58,59</sup>.

Zinc is also essential to the normal function of the immunological system, its deficiency being able to lead to thymic atrophy, lymphopenia, reduction of immunoglobulin mitosis, among other alterations. Damage also occurs in the mucous barrier of the gastrointestinal and pulmonary tract. The oxidative stress has often been related to the phases of initiation and promotion of the process of



carcinogenesis. The antioxidant enzymes, dependent upon selenium and zinc, which antagonize this process, are at low levels in the tumor cells<sup>60, 61</sup>.

Study done by McMillan et al<sup>62</sup> corroborated such data, when it was noted

that concentrations of plasmatic zinc of patients with gastrointestinal cancer were significantly lower when compared with healthy individuals. Such data indicates the importance of offering daily the recommendation of this mineral in oncological patients.

6 scoops  
daily of




**211**  
of added  
**CALORIES**

**13**  
grams of added  
**PROTEIN**


**284**  
milligrams of  
**OMEGA 3**

\* Omega-3 is from ALA (alpha-linolenic acid)



## RECOMMENDED SERVING SIZE

2 scoops per 4 ounces (120 mL)



## DIRECTIONS FOR USE

Use under medical supervision. Amount per day to be determined by medical professional and is dependent on age, body weight, and medical condition of the patient. Not for parenteral use.

**ENU Pro3 Plus** is soluble in liquids and moist foods with minimal effect on taste, texture, and volume. For enteral or oral use.

1. Measure **ENU Pro3 Plus** using the included scoop. A level scoop holds approximately 8.6g of powder.
2. Add powder to the desired volume of liquid and/or moist foods and stir continuously or use the aid of a blender until the powder has dissolved.
3. Once mixed with liquids or foods, keep refrigerated and consume within 12 hours.

## STORAGE CONDITIONS

Store at room temperature. Avoid excessive heat. Do not freeze. After opening canister, consume contents within 30 days. For expiration date, check the bottom of canister.

## INGREDIENTS

Maltodextrin, whey protein isolate, canola oil, fructooligosaccharides, milk protein concentrate, L-leucine, soybean oil, sodium citrate, potassium chloride, medium chain triglycerides, calcium phosphate, magnesium carbonate, choline citrate, potassium citrate, potassium phosphate, sodium ascorbate, zinc gluconate, ferrous gluconate, alpha-tocopherol acetate, beta-carotene, sodium selenate, nicotinamide, retinyl palmitate, phytonadione, sodium molybdate, manganese sulfate, calcium pantothenate, cholecalciferol, copper sulfate, chromium chloride, cyanocobalamin, pyridoxine hydrochloride, potassium iodide, riboflavin, thiamine, folic acid, biotin, silicon dioxide (anti-humectant).


**Contains milk and soy.**

## NUTRITION FACTS

	Per 8.6g Scoop (1 T)	Per 100g	Per 350g Container
Calories	35	409	1,432.0
Protein, g	2	25	89.2
Leucine, g	0.6	6.5	22.8
Total Fat, g	0.8	9.6	33.7
Saturated Fat, g	0.1	1.5	5.1
Trans Fat, g	0	0	0
Cholesterol, mg	0	0	0
Sodium, mg	33	389	1361.5
Total Carbohydrate, g	5	55	192.4
Dietary Fiber, g	0.5	6.1	21.3
Total Sugars, g	0	0	0
Includes Added Sugars, g	0	0	0
Sugar Alcohol, g	0	0	0
Vitamin A, mcg RAE	31.0	360.0	1,260.0
Vitamin C, mg	4.8	56.0	196.0
Vitamin D, mcg	0.3	3.8	13.3
Vitamin E, mg α-TE	0.2	2.8	20.0
Vitamin K, mcg	4.0	46.0	161.0
Thiamin (B1), mg	0.0	0.5	1.8
Riboflavin (B2), mg	0.0	0.5	1.8
Niacin (B3), mg NE	1.0	11.6	350.0
Vitamin B6, mg	0.1	0.7	2.3
Folate, mcg DFE	17.7	205.7	720.0
(Folic Acid, mcg)	10.4	121.0	423.5
Vitamin B12, mcg	0.1	0.9	3.2
Pantothenic Acid (B5), mg	0.2	1.9	6.7
Biotin, mcg	1.0	11.4	39.9
Choline, mg	10.3	120.0	420.0
Calcium, mg	30.7	357.2	1250.2
Chromium, mcg	1.1	13.3	46.6
Copper, mg	0.0	0.3	1.1
Iodine, mcg	4.8	55.9	195.7
Iron, mg	0.3	3.7	13.0
Magnesium, mg	8.2	95.0	332.5
Manganese, mg	0.1	0.9	3.1
Molybdenum, mcg	1.5	17.1	59.9
Phosphorus, mg	22.1	257.4	900.9
Selenium, mcg	3.5	40.5	141.8
Zinc, mg	0.5	6.1	23.4
Potassium, mg	56.5	657.0	2299.4
Chloride, mg	37.8	439.0	1536.4
Inositol, mg	0.0	0.0	0.0



33201  
Amazon US: A-USA-33201US 3



## FLEXIBLE AND CONVENIENT FOR GREATER ADHERENCE

An important point to be considered on the indication of oral nutritional therapy is the adhesion of the patient to the treatment proposed. Among the factors which can be associated with the low adhesion to the oral nutritional supplement is the monotony of the taste of the product indicated,

the palatability being a key factor in its acceptance<sup>63</sup>. Thus, the importance of monitoring and guidance by health professionals to ensure adhesion and obtain results favorable to the patient's evolution. As it is an unflavoured product, ENU can be added to any type of preparation, hot or

cold, sweet or salty, thereby allowing greater versatility in its means of presentation.

Its recommended daily dose can be fractionized throughout the day, in all the means, as per the patient's requirement and tolerance, allowing individualization of the treatment and greater adhesion thereto.

**TABLE 5:** Nutritional Recommendation vs. Estimate of consumption vs. ENU Pro3+<sup>17, 23, 25, 47, 64, 65, 66, 67</sup>

	NUTRITIONAL RECOMMENDATION	ESTIMATE OF CONSUMPTION (ADULT 70 KG)	ENU Pro3+* (ADULT 70 KG)
CALORIES	<b>Weight maintenance:</b> 20 - 30 kcal/kg/day <b>Weight gain:</b> 30 - 35 kcal/kg/day	1500 - 2100 kcal/day Avg = 1800 kcal/day 35% = 630 kcal	<b>630 kcal = 154g</b>
PROTEINS	1 a 2g/kg/dia	60 - 120g/day <b>Avg</b> = 90g/day 35% = 31.5g	<b>39.4g (44%)</b>
L-LEUCINE	<b>RDA:</b> 0.042 to 0.052g/kg/day <b>Studies:</b> Muscular mass increase 1.7 to 2.8g/meal	2,52 - 3.12g/day <b>Avg</b> = 2.82g/day 35% = 0.99g UL* = 35g	<b>7.2g</b>
FIBERS	15 to 30g/day 5 to 10g prebiotic fiber/day	35% = 7.8g 2,6g prebiotic	<b>9.4g prebiotic fiber (42%)</b>
MICRONUTRIENTS	<b>RDA:</b> 1x/day	35% RDA	<b>78% RDA</b>

*Adapted from Augusto ALP, In: Cotrim, TH20.*

*\*ENU information is calculated for ~35% of an adult daily diet for a person weighing 70kg. Nutrition values using 18 scoops/day.*

# BIBLIOGRAPHIC REFERENCES

1. Instituto Nacional de Câncer José Alencar Gomes da Silva. Coordenação Geral de Gestão Assistencial. Hospital do Câncer I. Serviço de Nutrição e Dietética. Consenso nacional de nutrição oncológica. / Instituto Nacional de Câncer José Alencar Gomes da Silva; Nivaldo Barroso de Pinho (organizador) - 2. ed. rev. ampl. atual. - Rio de Janeiro: INCA, 2016. 112p.: Il.; v. 2.
2. SHILS ME. Suporte nutricional do paciente com câncer. In: SHILS, M.E. et al. Tratado de nutrição moderna na saúde e na doença. 9.ed. São Paulo: Manole, 2003. v.2. p. 1385-1416.
3. BARRET M, MALKA D, APARICIO T et al. Nutritional status affects treatment tolerability and survival in metastatic colorectal cancer patients: results of an AGEO prospective multicenter study. *Oncology*, 2011; 81 (5-6): 395-402.
4. Union for International Cancer Control (UICC). World Cancer Declaration Progress Report 2016. Disponível em: <http://www.uicc.org/wcd-report>. Acesso em: 10/02/2017.
5. Instituto Nacional de Câncer José Alencar Gomes da Silva. Inquérito brasileiro de nutrição oncológica / Instituto Nacional de Câncer José Alencar Gomes da Silva; Câncer José Alencar Gomes da Silva; organização Cristiane Aline D'Almeida, Nivaldo Barroso de Pinho.- Rio de Janeiro: INCA, 2013.
6. ARENDS et al. ESPEN guidelines on nutrition in cancer patients, *Clinical Nutrition* (2016), <http://dx.doi.org/10.1016/j.clnu.2016.07.015>.
7. Martin L, Senesse P, Gioulbasanis I, Antoun S, Bozzetti F, Deans C, et al. Diagnostic criteria for the classification of cancer-associated weight loss. *J Clin Oncol* 2015;33:90e9.
8. ARGILÉS, J. M. Cancer-associated malnutrition. *European Journal of Oncology Nursing*, Edinburgh, v. 9, p. S39-S50, 2005.
9. ARGILÉS, J. M. et al. The role of cytokines in cancer cachexia. *Current Opinion in Supportive e Palliative Care*, Emigsville, v. 3.
10. FEARON K, STRASSER F, ANKER SD et al. Definition and classification of cancer cachexia: an international consensus. *Lancet Oncol*, 2011; 12: 489-95.
11. BLUM, D, OMLIN A, FEARON KC et al. Evolving classification systems for cancer cachexia: ready for clinical practice? *Supportive Care in Cancer*, 2010. 18(3): 273-9.
12. Fearon K et al. Definition and classification of cancer cachexia: an international consensus. *Lancet Oncol*, v.12, n.5, p.489-95, 2011.
13. ANDREYEV HJ, NORMAN AR, OATES J et al. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? *Eur J Cancer*. 1998. Mar; 34 (4): 503-09.
14. MARTIGNONI M, KUNZE P, FRIESS H. Cancer cachexia. *Mol Cancer*. 2003;(2):36-40.
15. ARGILES JM, BUSQUETS S, LÓPEZ-SORIANO FJ, et al., Are there any benefits of exercise training in cancer cachexia? *J Cachexia Sarcopenia Muscle*, 2012. Jun, 3(2): 73-76.
16. MUSCARITOLI M, BOSSOLA M, BELLANTONE R et al. Therapy of muscle wasting in cancer: what is the future? *Curr Opin Nutr Metab Care*. 2004;(7): 459-66.
17. TISDALE MJ. Cachexia in cancer patients. *Nature Rev Cancer*. 2002;(2): 862-71.
18. Silva MPN. Síndrome da anorexia-caquexia em portadores de câncer. *Revista brasileira de cancerologia*. 2006;52(1):59-77
19. CALIXTO-LIMA MARTINS DE ANDRADE E, GOMES AP et al. Dietetic management in gastrointestinal complications from antineoplastic chemotherapy. *Nutr Hosp*. 2012, 27; (1): 65-75.
20. COTRIM TH. Acompanhamento nutricional de pacientes em radioterapia e quimioterapia. In: *Nutrição em Oncologia*. 2003. Tecmedd, 1.a edição. p. 205-18.
21. CARNEIRO IP, MAZURAK VC, PRADO CM. Clinical implications of sarcopenic obesity in cancer. *Curr Oncol Rep*. 2016;18(10): 62.
22. MARTIN L, BIRDSELL L, MACDONALD N et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. *J Clin Oncol*. 2013;31(12):1539-47
23. Lynch GS, Schertzer JD, Ryall JG. Therapeutic approaches for muscle wasting disorders. *Pharmacol Ther* 2007; 113: 461-87.
24. BALDWIN C, SPIRO A, AHERN R et al., Oral nutritional interventions in malnourished patients with cancer: a systematic review and meta-analysis. *J. Natl Cancer Inst*, 2012. 104(5): 371-85.
25. RAVASCO PI, MONTEIRO G, CAMILLO M., Individualized nutrition intervention is of major benefit to colorectal cancer patients: long-term follow-up of a randomized controlled trial of nutritional therapy. *Am J Clin Nutr*, 2012. 96(6): 1346-53.
26. Ebad H, Salem A, Sayed A, Metwalli A. Whey protein enhances normal inflammatory responses during cutaneous wound healing in diabetic rats. *Lipids in Health and Disease*. 2011;10:235.
27. Marshall, K. Therapeutic Applications of Whey Protein. *Alternative Medicine Review*. 2004; 9:2
28. Tomé, D. The nutritional value of whey proteins, new insights. In *The Importance of Whey and Whey Components in Food and Nutrition* (pp. 295-302), Proceedings of the 3rd International Whey Conference. Munich, Germany, 2001.
29. Bounous, G. and Gold, P. (1991) The biological activity of undenatured dietary whey proteins: role of glutathione. *Clinical and Investigative Medicine* 14, 296-309.
30. Bounous, G., Batist, G., and Gold, P. (1989) Immunoenhancing property of dietary whey protein in mice: role of glutathione. *Clinical and Investigative Medicine* 12, 154-161.
31. Bounous, G., Batist, G., and Gold, P. (1991) Whey proteins in cancer prevention. *Cancer Letters* 57, 91-94.
32. Bounous, G., Papenburg, R., Kongshavn, P. A., Gold, P. and Fleischer, D. (1988a) Dietary whey protein inhibits the development of dimethylhydrazine induced malignancy. *Clinical and Investigative Medicine* 11, 213-217.
33. Bounous, G., Kongshavn, P. A. and Gold, P. (1988b) The immunoenhancing property of dietary whey protein concentrate. *Clinical and Investigative Medicine* 11, 271-278.
34. Moreno YMF. Influência das proteínas do soro de leite bovino no estado nutricional, composição corporal e sistema imune em coorte de crianças com síndrome da imunodeficiência adquirida (AIDS) [dissertação]. Campinas: Faculdade de Engenharia de Alimentos, Universidade Estadual de Campinas; 2002.

35. Walzem RL, Dillard CJ, German JB. Whey components: Millennia of evolution create functionalities for mammalian nutrition: what we know and what we may be overlooking. *Crit Rev Food Sci Nutr* 2002; 42:353-75.
36. SGARBIERI, Valdemiro Carlos. Propriedades fisiológicas/funcionais das proteínas do soro de leite. *Rev. Nutr.* []. 2004, 17, 4 [ 2017-02-24], pp.397-409
37. McIntosh GH, Le Leu RK. The influence of dietary proteins on colon cancer risk. *Nutr Res* 2001; 21:1053-66.
38. Piccolomini F, Iskandar M, Lands LC, Kubow S. High hydrostatic pressure pre-treatment of whey proteins enhances whey protein hydrolysate inhibition of oxidative stress and IL-8 secretion in intestinal epithelial cells. *Food Nutr Res* 2012;56:17549.
39. Da Silva MS, Rudkowska I. Dairy nutrients and their effect on inflammatory profile in molecular studies. *Mol Nutr Food Res*. 2015 Jul;59(7):1249-63.
40. Bordoni A, Danesi F, Dardevet D, Dupont D, Fernandez AS, Gille D, et al. Dairy products and inflammation: a review of the clinical evidence. *Crit Rev Food Sci Nutr* 2015
41. Panagiotakos D.B. Panagiotakos, C.H. Pitsavos, A.D. Zampelas, C.A. Chrysohoou, C.I. Stefanadis. Dairy products consumption is associated with decreased levels of inflammatory markers related to cardiovascular disease in apparently healthy adults: The ATTICA study *Journal of the American College of Nutrition*, 29 (2010), pp. 357-364
42. PATEL S. Functional food relevance of whey protein: A review of recent findings and scopes ahead. *Journal of Functional Foods Volume 19, Part A, December 2015, Pages 308-319*
43. Gillis C, Li C, Lee L, Awasthi R, Augustin B, Gamsa A, Liberman AS, Stein B, Charlebois P, Feldman LS, Carli F (2014) Prehabilitation versus rehabilitation: a randomized control trial in patients undergoing colorectal resection for cancer. *Anesthesiology* 121(5):937-947.
44. HAM DJ, CALDOW MK, LYNCH GS, Koopman R, Leucine as a treatment for muscle wasting: a critical review, *Clinical Nutrition*(2014), doi:10.1016/j.clnu.2014.09.016. Acesso em 05 de março de 2015.
45. Tayek JA, Bistran BR, Hehir DJ, Martin R, Moldawer LL, Blackburn GL. Improved protein kinetics and albumin synthesis by branched chain amino acid-enriched total parenteral nutrition in cancer cachexia. A prospective randomized crossover trial. *Cancer* 1986.
46. Burn GL, Bistran BR. Branched chain amino acids as the protein component of parenteral nutrition in cancer cachexia. *Br J Surg* 1989;76:149e53.
47. BOZETTI F, BOZETTI V. Is the intravenous supplementation of amino acid to cancer patients adequate? A critical appraisal of literature. *Clin Nutr* 2013;32:142-146.
48. KIMBALL SR, JEFFERSON LS. Signaling Pathways and Molecular Mechanisms through which Branched-Chain Amino Acids Mediate Translational Control of Protein Synthesis. *J. Nutr.* January 2006 vol. 136 no. 1 227S-231S
49. ENGLISH KL, METTLER JA, ELLISON JB, MAMEROW MM, ARENTSON-LANTZ E, PATTARINI JM, PLOUTZ-SNYDER R, SHEFFIELDMOORE M, PADDON-JONES D. Leucine partially protects muscle mass and function during bed rest in middle-aged adults. *Am J Clin Nutr* February 2016 vol. 103 no. 2 465-473
50. Katsanos CS, Kobayashi H, Sheffield-Moore M, Aarsland A, Wolfe RR. A high proportion of leucine is required for optimal stimulation of the rate of muscle protein synthesis by essential amino acids in the elderly. *Am J Physiol* 2006;291(2):E381e7.27.
51. Koopman R, Verdijk L, Manders RJ, Gijsen AP, Gorselink M, Pijpers E, et al. Co-ingestion of protein and leucine stimulates muscle protein synthesis rates to the same extent in young and elderly lean men. *Am J Clin Nutr* 2006;84(3): 623e32. 28.
52. Rieu I, Balage M, Sornet C, Giraudet C, Pujos E, Grizard J, et al. Leucine supplementation improves muscle protein synthesis in elderly men independently of hyperaminoacidaemia. *J Physiology* 2006;575(Pt 1):305e15.
53. Borsheim E, Bui QU, Tissier S, Kobayashi H, Ferrando AA, Wolfe RR. Effect of amino acid supplementation on muscle mass, strength and physical function in elderly. *Clin Nutr* 2008;27:189e95.
54. Dillon EL, Sheffield-Moore M, Paddon-Jones D, Gilkison C, Sanford AP, Casperson SL, et al. Amino acid supplementation increases lean body mass, basal muscle protein synthesis, and insulin-like growth factor-I expression in older women. *J Clin Endocrinol Metab* 2009;94:1630e7.
55. Bauer JM, Verlaan S, Bautmans I, Brandt K, et al. Effects of a vitamin D and leucine-enriched whey protein nutritional supplement on measures of sarcopenia in older adults, the PROVIDE study: a randomized, double-blind, placebo-controlled trial. *J Am Med Dir Assoc*. 2015 Sep 1;16(9):740-7
56. Eley HL, Russell ST, Tisdale MJ. Effect of branched-chain amino acids on muscle atrophy in cancer cachexia. *Biochem J* 2007;407:113e20
57. Winter A, Macadams J, Chevalier S. Normal protein anabolic response to hyperaminoacidemia in insulin-resistant patients with lung cancer cachexia. *Clin Nutr* 2012;31:765e73.
58. HAMBIDGE M. Human Zinc Deficiency. *J Nutr* 2000; 130: 1344-49.
59. GOTO T, KOMAI M, BRYANT BP et al. Reduction in carbonic anhydrase activity in the tongue epithelium and submandibular gland in and zinc-deficient rats. *Int J Nutr Res* 2000; 70: 110-18. 43. Komai M, Goto T, Suzuki H, Takeda T, Furukawa Y. Zinc 60. DELVES P.J., ROITT IM. The immune system: first of two parts. *N Engl J Med* 2000; 343: 37-49.
61. GRIGOLO, B., LISIGNOLI, G., TONEGUZZI, S et AL. Copper/zinc superoxide dismutase expression by different human osteosarcoma cell lines. *Anticancer Research, Athens*, v.18, n.2A, p.1175-1180, 1998
62. McMILLAN DC, SATTAR N, TALWAR D, et al. Changes in micronutrient concentrations following anti-inflammatory treatment in patients with gastrointestinal cancer. *Nutrition* 2000; 16: 425-28.
63. FADONI MRB, SICCHIERI JMF. Suplementos nutricionais e nutrição enteral. In: *Atualidades em alimentação e nutrição hospitalar*. Ed. Atheneu, 2017, 1ª edição. p215-224.
64. Bonetto A, Aydogdu T, Kunzevitky N, et al. STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. *PLoS One* 2011; 6:e22538.
65. BRENNER DA et al. Tumor necrosis factor- $\alpha$  inhibits albumin gene expression in a murine model of cachexia. *J. Clin. Invest.* 1990; 85: 248-55.
66. Carvalho G, Camilo ME, Ravasco P. Qual a relevância da nutrição em oncologia? *Acta Med Port.*, v.24, n.4, p. 1041-50, 2011.
67. Op den Kamp CM, Langen RC, Snepvangers FJ, et al. Nuclear transcription factor kappa B activation and protein turnover adaptations in skeletal muscle of patients with progressive stages of lung cancer cachexia. *Am J Clin Nutr* 2013; 98:738-748.
68. American Cancer Society. Cancer Statistics Center. <http://cancerstatisticscenter.cancer.org>. Accessed Feb. 27, 2020.



Visit [ENU-Nutrition.com](https://www.enu-nutrition.com) for more information.

Call **855-266-6733**, e-mail [Support@ENU-Nutrition.com](mailto:Support@ENU-Nutrition.com), or contact our sales representatives for samples.

[Support@ENU-Nutrition.com](mailto:Support@ENU-Nutrition.com)

| **855-266-6733**

| [ENU-Nutrition.com](https://www.enu-nutrition.com)

**CAMBROOKE™**

 **PRODIET**  
MEDICAL NUTRITION

Eat Well. Live Well.

  
**Ajinomoto**